论文部分内容阅读
1980年1月至1985年12月,中国医科大学附属第一医院肿瘤科收治胃癌、行胃切除术250例。行D_2或D_3式淋巴结根治清除术203例。无选择地对其中93例术后辅助MMC+FT_(207)化疗(A组)、110例未进行化疗(B组),做为对照。姑息切除47例,其中23例术后合并化疗(C组),24例未合并化疗(D组)。本文着重比较根治切除术后是否合并MMC+FT_(207)化疗的生存期,生存率,以期做出合理评价,指导临床应用。
From January 1980 to December 1985, the Department of Oncology of the First Affiliated Hospital of China Medical University received gastric cancer and performed gastrectomy in 250 cases. Radical removal of D_2 or D_3 lymph nodes was performed in 203 patients. There were no choices for 93 cases of postoperative adjuvant MMC+FT_(207) chemotherapy (group A) and 110 cases without chemotherapy (group B) as controls. Palliative resection was performed in 47 patients, of which 23 patients received postoperative chemotherapy (group C) and 24 patients did not receive chemotherapy (group D). This article focuses on comparing the survival and survival of MMC+FT_(207) chemotherapy after radical resection, in order to make a reasonable evaluation and guide the clinical application.